Literature DB >> 16806828

A new paradigm for West syndrome based on molecular and cell biology.

Mitsuhiro Kato1.   

Abstract

Symptomatic West syndrome has heterogeneous backgrounds. Recently, two novel genes, ARX and CDKL5, have been found to be responsible for cryptogenic West syndrome or infantile spasms. Both are located in the human chromosome Xp22 region and are mainly expressed and play roles in fetal brain. Moreover, several genes responsible for brain malformations including lissencephaly, which is frequently associated with West syndrome or infantile spasms, have been found, and the mechanisms responsible for the neural network disorders in these brain malformations are rapidly being determined. Findings of animal and in vitro studies and mutation analyses in humans are delineating the molecular and cellular basis of West syndrome. Mutations of the ARX gene controlling the development of GABAergic interneurons exhibit pleiotropic effects including lissencephaly with a strong genotype-phenotype correlation. An expansion mutation of the first polyalanine tract of ARX is more strongly related to infantile spasms than is that of the second polyalanine tract. Although the phenotype of CDKL5 mutation is similar to Rett syndrome caused by MECP2 mutation, the former is characterized by early-onset seizures and association with West syndrome. Lissencephaly caused by LIS1 or DCX mutation frequently results in West syndrome, while lissencephaly due to ARX mutation is associated with the most severe form of epilepsy but never results in West syndrome nor infantile spasms. Both LIS1 and DCX participate in the development of GABAergic interneurons as well as pyramidal neurons, while ARX participates only in that of interneurons. Individuals with lissencephaly due to ARX mutation lack non-pyramidal or GABAergic interneurons. ARX is crucial for the development of GABAergic interneuron, so abnormal interneurons in patients with ARX mutation are thought to be implicated in the pathological mechanism, even though brain MRI is normal. Abnormal interneurons appear to play an essential role in the pathogenesis of West syndrome or infantile spasms, which can be considered an interneuronopathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806828     DOI: 10.1016/j.eplepsyres.2006.02.008

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  17 in total

Review 1.  Balanced translocations in mental retardation.

Authors:  Geert Vandeweyer; R Frank Kooy
Journal:  Hum Genet       Date:  2009-04-05       Impact factor: 4.132

2.  The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis.

Authors:  Fanny Kortüm; Soma Das; Max Flindt; Deborah J Morris-Rosendahl; Irina Stefanova; Amy Goldstein; Denise Horn; Eva Klopocki; Gerhard Kluger; Peter Martin; Anita Rauch; Agathe Roumer; Sulagna Saitta; Laurence E Walsh; Dagmar Wieczorek; Gökhan Uyanik; Kerstin Kutsche; William B Dobyns
Journal:  J Med Genet       Date:  2011-03-25       Impact factor: 6.318

3.  Dominant-negative mutations in alpha-II spectrin cause West syndrome with severe cerebral hypomyelination, spastic quadriplegia, and developmental delay.

Authors:  Hirotomo Saitsu; Jun Tohyama; Tatsuro Kumada; Kiyoshi Egawa; Keisuke Hamada; Ippei Okada; Takeshi Mizuguchi; Hitoshi Osaka; Rie Miyata; Tomonori Furukawa; Kazuhiro Haginoya; Hideki Hoshino; Tomohide Goto; Yasuo Hachiya; Takanori Yamagata; Shinji Saitoh; Toshiro Nagai; Kiyomi Nishiyama; Akira Nishimura; Noriko Miyake; Masayuki Komada; Kenji Hayashi; Syu-Ichi Hirai; Kazuhiro Ogata; Mitsuhiro Kato; Atsuo Fukuda; Naomichi Matsumoto
Journal:  Am J Hum Genet       Date:  2010-05-20       Impact factor: 11.025

4.  Biallelic Variants in CNPY3, Encoding an Endoplasmic Reticulum Chaperone, Cause Early-Onset Epileptic Encephalopathy.

Authors:  Hiroki Mutoh; Mitsuhiro Kato; Tenpei Akita; Takuma Shibata; Hiroyuki Wakamoto; Hiroko Ikeda; Hiroki Kitaura; Kazushi Aoto; Mitsuko Nakashima; Tianying Wang; Chihiro Ohba; Satoko Miyatake; Noriko Miyake; Akiyoshi Kakita; Kensuke Miyake; Atsuo Fukuda; Naomichi Matsumoto; Hirotomo Saitsu
Journal:  Am J Hum Genet       Date:  2018-01-27       Impact factor: 11.025

5.  Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms.

Authors:  Jason T Lerner; Noriko Salamon; Raman Sankar
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-08       Impact factor: 2.570

6.  A longer polyalanine expansion mutation in the ARX gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome).

Authors:  Mitsuhiro Kato; Shinji Saitoh; Atsushi Kamei; Hideaki Shiraishi; Yuki Ueda; Manami Akasaka; Jun Tohyama; Noriyuki Akasaka; Kiyoshi Hayasaka
Journal:  Am J Hum Genet       Date:  2007-06-11       Impact factor: 11.025

7.  A patient-specific induced pluripotent stem cell model for West syndrome caused by ST3GAL3 deficiency.

Authors:  Laura van Diepen; Falk F R Buettner; Dirk Hoffmann; Christina T Thiesler; Oliver von Bohlen Und Halbach; Viola von Bohlen Und Halbach; Lars R Jensen; Doris Steinemann; Simon Edvardson; Orly Elpeleg; Axel Schambach; Rita Gerardy-Schahn; Andreas W Kuss
Journal:  Eur J Hum Genet       Date:  2018-08-08       Impact factor: 4.246

Review 8.  Neonatal and Infantile Epilepsy: Acquired and Genetic Models.

Authors:  Aristea S Galanopoulou; Solomon L Moshé
Journal:  Cold Spring Harb Perspect Med       Date:  2015-12-04       Impact factor: 6.915

9.  A triplet repeat expansion genetic mouse model of infantile spasms syndrome, Arx(GCG)10+7, with interneuronopathy, spasms in infancy, persistent seizures, and adult cognitive and behavioral impairment.

Authors:  Maureen G Price; Jong W Yoo; Daniel L Burgess; Fang Deng; Richard A Hrachovy; James D Frost; Jeffrey L Noebels
Journal:  J Neurosci       Date:  2009-07-08       Impact factor: 6.167

Review 10.  Convulsing toward the pathophysiology of autism.

Authors:  Roberto Tuchman; Solomon L Moshé; Isabelle Rapin
Journal:  Brain Dev       Date:  2008-11-08       Impact factor: 1.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.